Euroespes S.A. | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2011
2012
2013
2014
2015
Sales/Revenue
2,999.90
2,621.60
2,327.40
2,210.50
2,482.10
Cost of Goods Sold (COGS) incl. D&A
2,933.30
2,983.30
1,588.60
1,316.40
1,122.10
Gross Income
66.60
361.80
738.80
894.00
1,360.00
SG&A Expense
-
-
591.90
628.10
962.30
EBIT
43.00
361.80
54.00
179.00
316.80
Unusual Expense
15.80
109.20
-
-
-
Non Operating Income/Expense
15.50
165.20
0.90
69.10
2.40
Interest Expense
20.40
17.60
26.10
73.00
132.50
Pretax Income
25.90
652.30
29.80
179.00
186.70
Income Tax
107.80
8.60
-
-
16.40
Equity in Affiliates
-
-
-
-
4.10
Consolidated Net Income
81.90
643.70
29.80
179.00
207.20
Net Income
81.90
643.70
29.80
179.00
207.20
Net Income After Extraordinaries
81.90
643.70
29.80
179.00
207.20
Net Income Available to Common
81.90
643.70
29.80
179.00
207.20
EPS (Basic)
0.02
0.12
0.01
0.04
0.04
Basic Shares Outstanding
5,449.20
5,401.10
5,440.50
4,492.20
4,734.20
EPS (Diluted)
-
0.12
0.01
0.04
0.04
Diluted Shares Outstanding
-
5,401.10
5,440.50
4,492.20
4,734.20
EBITDA
146.90
155.00
254.40
385.40
615.60
Other Operating Expense
109.60
-
93.00
86.90
81.00
Non-Operating Interest Income
6.20
1.40
1.10
3.90
0.00

About Euroespes

View Profile
Address
Biomedical Research Center
Bergondo Galicia 15165
Spain
Employees -
Website http://www.euroespes.com
Updated 07/08/2019
EuroEspes SA engages in the provision of biomedical services. It also engages in the design and implementation of prevention programs for diseases of the central nervous system. Its business model involves investigating possible causes of central nervous system disorders.